Where HSCI comes in

Meet the new medicines, page 6

HSCI researchers, based in laboratories at Harvard University and its affiliated hospitals, are dedicated to making discoveries in gene and cell therapies.

HSCI fosters collaboration to enable scientists throughout Harvard to:

  • Investigate the underlying biology so we can understand how, why, and if these therapies can work without harming us.
  • Explore better, more efficient ways to produce cells that could save patients’ lives.
  • Work across industry and academia to find new ways to simplify all the steps involved in making cell and gene therapies.
  • Collaborate with bioengineers to discover new solutions that leverage advances in genetics, stem cell biology, regenerative medicine, and biomaterials.

The goal of this work is to cure people of disease in a completely different way. New understanding and innovation will transform the way we make and use all types of medicines, including gene and cell therapies.

Find out more

US Food and Drug Administration explainer, "What is gene therapy?"

Kit Parker’s thin films together with Bill Pu’s cardiomyocytes let to a new in vitro heart muscle that could one day be used for a heart patch.

Semma, a company launched by HSCI faculty, is encapsulating beta cells to hide them from the immune system. They are working on a device that separates out and shields beta cells so that they can sense glucose and send the right signals, without being exposed to attack.

Moderna, a company launched by HSCI faculty, is the forerunner in the field of mRNA treatments. Moderna has 10 of its programs and 20 products in clinical trials, and on 7 December 2018 launched the largest-ever initial public offering (IPO) of a venture-backed biotech company.